What is it about?
In this manuscript , we confirmed that efficacy of Imatinib mesylate in subjects with relapsed/refractory neuroblastoma associates with low Imatinib concentration. Low concentration appear to favor the activation of innate immune cells, like NK cells, in the bone marrow compartment, i.e. the site of neoplastic cells infiltration.
Featured Image
Why is it important?
Given the low rate of clinical response in subjects with relapsed/refractory neuroblastoma, the demonstration of 12% of overall survival at 10 year supports the inclusion of this drug in new Phase II trials for these subjects.
Perspectives
It was very important to further investigate potential mechanisms of efficacy of Imatinib mesylate in view of a longer follow-up and increased knowledge on its off-target effect, as was strongly suggested by our late collegue.
Maria Valeria Corrias
Read the Original
This page is a summary of: Updated clinical and biological information from the two-stage phase II study of imatinib mesylate in subjects with relapsed/refractory neuroblastoma, OncoImmunology, June 2018, Taylor & Francis,
DOI: 10.1080/2162402x.2018.1468953.
You can read the full text:
Contributors
The following have contributed to this page
